Skip to main content
American Journal of Respiratory and Critical Care Medicine logoLink to American Journal of Respiratory and Critical Care Medicine
. 2020 Sep 1;202(5):748–749. doi: 10.1164/rccm.202003-0828IM

A Novel Viral Epidemic Collides with an Ancient Scourge: COVID-19 Associated with Tuberculosis

Todd Cutler 1, David Scales 1, William Levine 1, Neil Schluger 2,3,*, Max O’Donnell 2,3
PMCID: PMC7462403  PMID: 32609542

A 61-year-old man with a history of Parkinson's disease presented with a history of 4 days of cough and fever to an emergency department in New York City. He described acute high-grade fever and cough with a background of 4 months of cough with occasional blood-streaked sputum. He was a New York City resident originally from China; he reported no known sick contacts or recent travel. Chest radiograph demonstrated a dense left basilar opacity (Figure 1), and point-of-care ultrasound revealed a left pleural effusion with compressive atelectasis (Video E1 in the online supplement). Patient was placed in respiratory and contact isolation because of concern about coronavirus disease (COVID-19) as well as tuberculosis (TB). Initial workup included a nasal pharyngeal swab, which tested positive by RT-PCR for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Complete blood count revealed lymphopenia (absolute lymphocyte count 935 cells/μl), and other routine laboratory values were within normal limits. A thoracentesis was performed, and 1.5 L of bloody, lymphocyte-predominant pleural fluid was removed. Sputum stained for acid-fast bacilli revealed moderate mycobacteria, and Gene-Xpert MTB/RIF sputum assay confirmed Mycobacterium tuberculosis.

Figure 1.

Figure 1.

Portable anteroposterior chest radiograph on hospital Day 1 demonstrating left lower lung opacities and moderate effusion with atelectasis/consolidation (*).

The patient was initiated on hydroxychloroquine for putative antiviral activity against SARS-CoV-2 and started on standard isoniazid, rifampin, ethambutol, and pyrazinamide for TB treatment. Initially, he required nasal canula oxygen supplementation at 2 L/min to maintain a normal oxygen saturation. Over time, the patient improved clinically: his supplemental oxygen requirements resolved, sputum acid-fast stain for bacilli converted to negative ×3, repeat nasopharyngeal swab RT-PCR for SARS-CoV-2 was negative, and he was successfully discharged to home to complete his TB treatment course.

Chronic lung disease is a risk factor for severe disease and mortality from COVID-19 (1), and more data is needed to determine whether it increases risk of infection. SARS-CoV-2 infection induces severe lymphopenia, with preferential effects on CD4+ (cluster of differentiation 4–positive) T cells (2), whose depletion may increase the risk of reactivation of TB. In addition, limited data suggests that active TB or TB infection may be associated with more severe COVID-19 presentation (3). Clinicians should maintain an active index of suspicion for TB in COVID-19 guided by clinical presentation potentially inconsistent with COVID-19 (e.g., chronicity of symptoms, weight loss, or pleural effusions) and epidemiologic risk factors identifying increased TB risk.

Supplementary Material

Supplements
Author disclosures

Footnotes

Author Contributions: Conception: T.C., D.S., W.L., and M.O’D. Analysis and interpretation: T.C., D.S., W.L., N.S., and M.O’D. Drafting the manuscript: T.C., D.S., W.L., N.S., and M.O’D.

This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org.

Originally Published in Press as DOI: 10.1164/rccm.202003-0828IM on July 1, 2020

Author disclosures are available with the text of this article at www.atsjournals.org.

References

  • 1.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–2629. doi: 10.1172/JCI137244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Liu Y, Bi L, Chen Y, Wang Y, Fleming J, Yu Y, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity [preprint] medRxiv. 2020 [accessed 2020 Mar 16]. Available from: https://www.medrxiv.org/content/10.1101/2020.03.10.20033795v1.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplements
Download video file (1.8MB, wmv)
Author disclosures

Articles from American Journal of Respiratory and Critical Care Medicine are provided here courtesy of American Thoracic Society

RESOURCES